MedTrace Logo

A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

NCT06542874 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 448

Last updated 2025-12-29

No results posted yet for this study

Summary

The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.

Conditions

  • Type 2 Diabetes (T2D)

Interventions

DRUG

NNC0487-0111 subcutanous

NNC0487-0111 administered subcutanously (under the skin)

DRUG

Placebo (NNC0487-0111 subcutanous)

NNC0487-0111 placebo administered subcutanously (under the skin)

DRUG

NNC0487-0111 oral

NNC0487-0111 administered orally (in the mouth)

DRUG

Placebo (NNC0487-0111 oral)

NNC0487-0111 placebo administered orally (in the mouth)

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency (dept. 2834) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-07
Primary Completion
2025-10-01
Completion
2025-10-24
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • Croatia
  • Germany
  • Greece
  • Hungary
  • Japan
  • Poland
  • Romania
  • Slovakia
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06542874 on ClinicalTrials.gov